These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 8151587

  • 1. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate.
    Carroll GJ, Thomas R, Phatouros CC, Atchison MH, Leslie AL, Cook NJ, D'Souza I.
    J Rheumatol; 1994 Jan; 21(1):51-4. PubMed ID: 8151587
    [Abstract] [Full Text] [Related]

  • 2. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis.
    Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M, Mimori T, Akizuki M, Ikeda Y.
    J Rheumatol; 1997 Dec; 24(12):2299-303. PubMed ID: 9415631
    [Abstract] [Full Text] [Related]

  • 3. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis.
    McKendry RJ, Dale P.
    J Rheumatol; 1993 Nov; 20(11):1850-6. PubMed ID: 8308769
    [Abstract] [Full Text] [Related]

  • 4. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R, Schleusser B, Herborn G, Karger T.
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [Abstract] [Full Text] [Related]

  • 5. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F, Michaud K.
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [Abstract] [Full Text] [Related]

  • 6. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.
    Kent PD, Luthra HS, Michet C.
    J Rheumatol; 2004 Sep; 31(9):1727-31. PubMed ID: 15338491
    [Abstract] [Full Text] [Related]

  • 7. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H, Ohno S, Ishigatsubo Y.
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [Abstract] [Full Text] [Related]

  • 8. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
    Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS.
    J Am Acad Dermatol; 2005 Feb; 52(2):262-7. PubMed ID: 15692471
    [Abstract] [Full Text] [Related]

  • 9. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F, Michaud K.
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [Abstract] [Full Text] [Related]

  • 10. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study.
    Luis M, Pacheco-Tena C, Cazarín-Barrientos J, Lino-Pérez L, Goycochea MV, Vazquez-Mellado J, Burgos-Vargas R.
    Arthritis Rheum; 1999 Oct; 42(10):2160-5. PubMed ID: 10524688
    [Abstract] [Full Text] [Related]

  • 11. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

  • 12. Factors influencing length of time taking methotrexate in rheumatoid arthritis.
    Ortendahl M, Schettler JD, Fries JF.
    J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279
    [Abstract] [Full Text] [Related]

  • 13. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
    Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P.
    Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189
    [Abstract] [Full Text] [Related]

  • 14. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis.
    Hoekstra M, van de Laar MA, Bernelot Moens HJ, Kruijsen MW, Haagsma CJ.
    J Rheumatol; 2003 Nov; 30(11):2325-9. PubMed ID: 14677172
    [Abstract] [Full Text] [Related]

  • 15. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
    Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, Barclay ML.
    Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853
    [Abstract] [Full Text] [Related]

  • 16. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE.
    Arthritis Res Ther; 2006 Aug; 8(5):R151. PubMed ID: 16984661
    [Abstract] [Full Text] [Related]

  • 17. [Dyspnea during administration of methotrexate: not anything to treat casually].
    van der Veen MJ, Teding van Berkhout F, Bijlsma JW.
    Ned Tijdschr Geneeskd; 1991 Mar 23; 135(12):522-5. PubMed ID: 2027397
    [Abstract] [Full Text] [Related]

  • 18. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study.
    Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisemandle W, Mekki QA, Tacrolimus-Methotrexate Rheumatoid Arthritis Study Group.
    Arthritis Rheum; 2003 Oct 23; 48(10):2763-8. PubMed ID: 14558080
    [Abstract] [Full Text] [Related]

  • 19. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2006 Feb 23; 33(2):248-55. PubMed ID: 16358365
    [Abstract] [Full Text] [Related]

  • 20. The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis.
    Johns KR, Littlejohn GO.
    J Rheumatol; 1999 Oct 23; 26(10):2110-3. PubMed ID: 10529125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.